AlzeCure Pharma AB (publ) (ALZCUR.ST)
SEK 1.17
(0.0%)
SEK 1.17
(0.0%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 3.05 Million | -99.91 Million | -70.63 Million | -69.5 Million | -50.28 Million | -36.27 Million |
| Net Income | -37.16 Million | -56.44 Million | -77.92 Million | -71.57 Million | -50.9 Million | -35.89 Million |
| Depreciation & Amortization | 476 Thousand | 570 Thousand | 576 Thousand | 495 Thousand | 290 Thousand | 104 Thousand |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | 39.74 Million | -44.24 Million | 6.56 Million | 1.36 Million | 283 Thousand | -392 Thousand |
| Other non-cash items | -38.76 Million | 203 Thousand | 145 Thousand | 213 Thousand | 50 Thousand | -93 Thousand |
| Investing Cash Flow | 7000.00 | - | -54 Thousand | -671 Thousand | -1.46 Million | -459 Thousand |
| Investments in PPE | - | - | -54 Thousand | -671 Thousand | -1.46 Million | -459 Thousand |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | 7000.00 | - | - | - | - | - |
| Other Investing Activities | 7.00 | - | - | - | - | - |
| Financing Cash Flow | 459 Thousand | 83.74 Million | - | 114 Thousand | -304 Thousand | 217.33 Million |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | -381 Thousand | - |
| Common Stock Issuance | 459 Thousand | 83.74 Million | - | 114 Thousand | 77 Thousand | 217.33 Million |
| Other Financing Activities | 39 Thousand | 83.74 Thousand | - | 114.00 | -304.00 | 217.33 Thousand |
| Accounts receivables | 41.87 Million | -41.92 Million | 4.56 Million | 394 Thousand | 148 Thousand | -859 Thousand |
| Accounts payables | -2.15 Million | -1.12 Million | 2 Million | 969 Thousand | -649 Thousand | 2.31 Million |
| Inventory | - | - | -4553.00 | -386.00 | - | - |
| Other working capital | 31 Thousand | -1.19 Million | 4553.00 | 386.00 | 784 Thousand | -1.84 Million |
| Cash at beginning of period | 25.57 Million | 41.74 Million | 112.43 Million | 182.49 Million | 234.54 Million | 53.95 Million |
| Cash at end of period | 29.1 Million | 25.57 Million | 41.74 Million | 112.43 Million | 182.49 Million | 234.54 Million |
| Capital Expenditure | - | - | -54 Thousand | -671 Thousand | -1.46 Million | -459 Thousand |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | 3.52 Million | -16.16 Million | -70.69 Million | -70.06 Million | -52.05 Million | 180.59 Million |
| Free Cash Flow | 3.05 Million | -99.91 Million | -70.69 Million | -70.17 Million | -51.74 Million | -36.73 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -8.65 Million | -9.99 Million | -9.75 Million | -37.16 Million | -7.96 Million | -10.49 Million |
| Depreciation & Amortization | 69 Thousand | 109 Thousand | 110 Thousand | 476 Thousand | 109 Thousand | 125 Thousand |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -594 Thousand | -368 Thousand | 1.28 Million | 39.74 Million | -225 Thousand | 1.18 Million |
| Other non-cash items | 866 Thousand | 567.00 | -476 Thousand | -38.76 Million | 314 Thousand | 286 Thousand |
| Investing Cash Flow | - | - | - | 7000.00 | 7000.00 | - |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | 7000.00 | 7000.00 | - |
| Other Investing Activities | - | - | - | 7.00 | - | - |
| Financing Cash Flow | 34.05 Million | - | - | 459 Thousand | -7000.00 | 420 Thousand |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 34.05 Million | - | - | 459 Thousand | - | 420 Thousand |
| Other Financing Activities | 34.05 Thousand | - | - | 39 Thousand | -7000.00 | -39 Thousand |
| Accounts receivables | 241 Thousand | -859.00 | -76 Thousand | 41.87 Million | -157 Thousand | 1.24 Million |
| Accounts payables | -969 Thousand | 567 Thousand | 772 Thousand | -2.15 Million | -57 Thousand | 140 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | 134 Thousand | -76.00 | 589 Thousand | 31 Thousand | -11 Thousand | -204 Thousand |
| Cash at beginning of period | 19.03 Million | 29.1 Million | 37.46 Million | 25.57 Million | 45.23 Million | 53.71 Million |
| Cash at end of period | 43.91 Million | 19.03 Million | 29.1 Million | 29.1 Million | 37.46 Million | 45.23 Million |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | 24.87 Million | -10.06 Million | -8.36 Million | 3.52 Million | -7.77 Million | -8.48 Million |
| Free Cash Flow | -9.17 Million | -10.06 Million | -8.36 Million | 3.05 Million | -7.77 Million | -8.9 Million |
ELBM
BYON
FCIC
HMLA
017810
FIBIH